Evidence map›Paper›PMID 25805500›Full record

ArticleThe Journal of biological chemistry2015

Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities.

Joerg Kumbrink, Shefali Soni, Barbara Laumbacher, Barbara Loesch, Kathrin H Kirsch

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joerg KumbrinkFrom the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.
Shefali SoniFrom the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.
Barbara Laumbacherthe Immunotherapy Research Center, Pettenkoferstrasse 8, 80336 Munich, Germany, and.
Barbara LoeschImmunis e.V., Pettenkoferstrasse 8, 80336 Munich, Germany.
Kathrin H KirschFrom the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, kirschk@bu.edu.
Boston University · US

Funding

Functional role of p130Cas/BCAR1 in breast cancerR01CA106468 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KIRSCH, KATHRIN H · 2005 to 2009
$1.4M
NCI NIH HHS CA106468NCI NIH HHS R01 CA106468
6 · The paper itself

Abstract

Elevated levels of p130(Cas) (Crk-associated substrate)/BCAR1 (breast cancer antiestrogen resistance 1 gene) are associated with aggressiveness of breast tumors. Following phosphorylation of its substrate domain, p130(Cas) promotes the integration of protein complexes involved in multiple signaling pathways and mediates cell proliferation, adhesion, and migration. In addition to the known BCAR1-1A (wild-type) and 1C variants, we identified four novel BCAR1 mRNA variants, generated by alternative first exon usage (1B, 1B1, 1D, and 1E). Exons 1A and 1C encode for four amino acids (aa), whereas 1D and 1E encode for 22 aa and 1B1 encodes for 50 aa. Exon 1B is non-coding, resulting in a truncated p130(Cas) protein (Cas1B). BCAR1-1A, 1B1, and variant 1C mRNAs were ubiquitously expressed in cell lines and a survey of human tissues, whereas 1B, 1D, and 1E expression was more restricted. Reconstitution of all isoforms except for 1B in p130(Cas)-deficient murine fibroblasts induced lamellipodia formation and membrane ruffling, which was unrelated to the substrate domain phosphorylation status. The longer isoforms exhibited increased binding to focal adhesion kinase (FAK), a molecule important for migration and adhesion. The shorter 1B isoform exhibited diminished FAK binding activity and significantly reduced migration and invasion. In contrast, the longest variant 1B1 established the most efficient FAK binding and greatly enhanced migration. Our results indicate that the p130(Cas) exon 1 variants display altered functional properties. The truncated variant 1B and the longer isoform 1B1 may contribute to the diverse effects of p130(Cas) on cell biology and therefore will be the target of future studies.

Indexed as

Gene Expression Regulation, EnzymologicAlternative SplicingAnimalsBase SequenceCell AdhesionCell MovementCrk-Associated Substrate ProteinExonsFibroblastsFocal Adhesion Protein-Tyrosine KinasesHumansMiceMolecular Sequence DataNeoplasm InvasivenessProtein IsoformsProtein Structure, TertiaryBCAR1 protein, humanCrk-Associated Substrate ProteinFocal Adhesion Protein-Tyrosine KinasesProtein IsoformsRNA, Messengeralternative splice variantscancer biologycell migrationcell signalingexon 1N-terminal SH3 domain extensionsp130CasPTK2 protein tyrosine kinase 2 (PTK2) (focal adhesion kinase) (FAK)SH3 domain bindingsignal transduction

Identifiers

PMID25805500
PMCPMC4424356
OpenAlexW2087323302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.